252 related articles for article (PubMed ID: 20237552)
1. Drug discovery: inhibitors that activate.
Cichowski K; Jänne PA
Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
[No Abstract] [Full Text] [Related]
2. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery: How melanomas bypass new therapy.
Solit D; Sawyers CL
Nature; 2010 Dec; 468(7326):902-3. PubMed ID: 21164474
[No Abstract] [Full Text] [Related]
5. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
6. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
7. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
[TBL] [Abstract][Full Text] [Related]
8. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
[TBL] [Abstract][Full Text] [Related]
9. Parsing out the complexity of RAF inhibitor resistance.
McMahon M
Pigment Cell Melanoma Res; 2011 Apr; 24(2):361-5. PubMed ID: 21392366
[No Abstract] [Full Text] [Related]
10. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling.
McKay MM; Ritt DA; Morrison DK
Curr Biol; 2011 Apr; 21(7):563-8. PubMed ID: 21458265
[TBL] [Abstract][Full Text] [Related]
11. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
12. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound stimulates NF-kappaB activation and iNOS expression via the Ras/Raf/MEK/ERK signaling pathway in cultured preosteoblasts.
Hou CH; Lin J; Huang SC; Hou SM; Tang CH
J Cell Physiol; 2009 Jul; 220(1):196-203. PubMed ID: 19288477
[TBL] [Abstract][Full Text] [Related]
14. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
15. Rit contributes to nerve growth factor-induced neuronal differentiation via activation of B-Raf-extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades.
Shi GX; Andres DA
Mol Cell Biol; 2005 Jan; 25(2):830-46. PubMed ID: 15632082
[TBL] [Abstract][Full Text] [Related]
16. Is BRAF the Achilles' Heel of thyroid cancer?
Chiloeches A; Marais R
Clin Cancer Res; 2006 Mar; 12(6):1661-4. PubMed ID: 16551846
[No Abstract] [Full Text] [Related]
17. Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
Ammar UM; Abdel-Maksoud MS; Oh CH
Eur J Med Chem; 2018 Oct; 158():144-166. PubMed ID: 30216849
[TBL] [Abstract][Full Text] [Related]
18. Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.
Scardaci R; Berlinska E; Scaparone P; Vietti Michelina S; Garbo E; Novello S; Santamaria D; Ambrogio C
Mol Oncol; 2024 Jun; 18(6):1355-1377. PubMed ID: 38362705
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
20. Clinical Translation of Combined MAPK and Autophagy Inhibition in
Lee JJ; Jain V; Amaravadi RK
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
